These are detailed in the Methods section.
ReviewSputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis
Introduction
Tuberculosis is a major global health problem with 9 million new cases and almost 2 million deaths per year.1 WHO recommends that patients with previously untreated pulmonary tuberculosis receive a four-drug regimen during the 2-month initial phase of treatment that includes rifampicin.2 The overall rate of failure or relapse (poor outcome) in patients receiving short-course directly observed treatment with a rifampicin-containing regimen is low.3, 4, 5 In patients receiving 6-month regimens who have drug-susceptible organisms, the estimated failure rate is 1–4% and the relapse rate 7% or less.3 Relapse of tuberculosis continues to place a substantial burden on patients and tuberculosis control programmes; in 2007, at least 270 000 patients worldwide returned after relapse (5% of tuberculosis notifications).1 Early identification of patients who have an increased risk of a poor outcome, coupled with an intervention such as treatment modification, could potentially reduce this burden.
Previous treatment guidelines have recommended the examination of a sputum smear at the end of the 2-month initial phase of treatment and, if the smear is positive, to continue the initial phase for an extra month before proceeding with the standard 4-month or 6-month continuation phase.6 These recommendations, designed for low-resource settings that lack the ability to do culture or drug-susceptibility testing, have been questioned due to lack of evidence, and the ability of a positive sputum examination result to predict poor outcome has not been fully assessed.7, 8, 9, 10, 11, 12 A recently published review on tuberculosis biomarkers identified an inverse relation between 2-month sputum-culture conversion and relapse, although the use of 2-month culture conversion as a guide to treatment of individual patients was limited by poor positive predictive value (PPV).13 However, the review was not a systematic review of all available evidence.
To estimate the accuracy of a positive sputum smear or culture for predicting poor outcome in patients with pulmonary tuberculosis who received a standardised regimen that included rifampicin in the initial phase, we did a systematic review and meta-analysis. In addition to estimating the accuracy of the sputum examination result, the quality of studies was appraised. Results from this systematic review were used in the development of the most recent WHO tuberculosis treatment guidelines.2
Section snippets
Methods
We used standard methods for systematic reviews of diagnostic accuracy studies.14, 15, 16, 17
Results
The searches of published work identified more than 12 000 citations, from which 15 papers (28 studies) were selected (figure 1).7, 9, 12, 20, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 Table 1 summarises study quality, and Table 2, Table 3 show characteristics of individual studies by relapse (18 studies) or treatment failure (ten studies), respectively. 23 (82%) studies were done in low-income countries. Most studies assessed the examination of a sputum sample at month 2, consistent with
Discussion
We did a systematic review and meta-analysis of the accuracy of sputum examination during treatment to identify pulmonary tuberculosis patients who will fail treatment or experience relapse. We found low sensitivity and moderate specificity for prediction of relapse or failure in all studies, irrespective of sputum examination or time of assessment. These results were similar for individual studies and pooled analyses.
If an individual's status is unknown, predictive values are used to estimate
Search strategy and selection criteria
References (50)
- et al.
Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial
Lancet
(2004) - et al.
Biomarkers for tuberculosis disease activity, cure, and relapse
Lancet Infect Dis
(2009) - et al.
Diagnosis and treatment of tuberculosis in children
Lancet Infect Dis
(2003) Sputum smear conversion during directly observed treatment for tuberculosis
Tuber Lung Dis
(1996)- et al.
Biomarkers of treatment response in clinical trials of novel antituberculosis agents
Lancet Infect Dis
(2007) Global tuberculosis control 2009: epidemiology, strategy, financing [WHO/HTM/TB/2009.411]
Treatment of tuberculosis guidelines (4th edn)
- et al.
Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally
JAMA
(2005) - et al.
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons
AIDS
(1999) Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis
Am Rev Respir Dis
(1987)
Treatment of tuberculosis: guidelines for national programmes (3rd edn) [WHO/CDS/TB/2003.313]
Should we take a history of prior treatment, and check sputum status at 2–3 months when treating patients for tuberculosis?
Int J Tuberc Lung Dis
Appropriateness of extending the intensive phase of treatment based on smear results
Int J Tuberc Lung Dis
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial
Lancet
Shortening the treatment of tuberculosis
Nat Biotechnol
Sputum microscopy results at two and three months predict outcome of tuberculosis treatment
Int J Tuberc Lung Dis
Conducting systematic reviews of diagnostic studies: didactic guidelines
BMC Med Res Methodol
Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer
AJR Am J Roentgenol
Systematic reviews of diagnostic test evaluations: what's behind the scenes?
ACP J Club
Systematic reviews of diagnostic test accuracy
Ann Intern Med
Tuberculosis
Two-year follow-up of directly-observed intermittent regimens for smear-positive pulmonary tuberculosis in China
Int J Tuberc Lung Dis
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews
BMC Med Res Methodol
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
BMJ
A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations
Stat Med
Cited by (207)
Tuberculosis treatment monitoring tests during routine practice: study design guidance
2024, Clinical Microbiology and InfectionMolecular Imaging of Tuberculosis
2023, Seminars in Nuclear MedicineTranscriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatment
2022, eBioMedicineCitation Excerpt :The mechanisms underlying DM-induced TB treatment failure remain, however, poorly understood. Prediction of TB treatment failure based on sputum-smear microscopy and mycobacterial culture lacks sensitivity10 and depends on the quality of sputum samples, which are difficult to collect and are frequently inconsistent in quality.11–13 As well as more advanced sputum-based diagnostics, monitoring of whole blood transcriptomics may be an additional, complementary but independent, method to monitor treatment responses, possibly with increased sensitivity.14
Risk factors for pulmonary tuberculosis recurrence, relapse and reinfection: A systematic review and meta-analysis
2024, BMJ Open Respiratory Research